HOUSE_OVERSIGHT_028420.jpg
3.32 MB
Extraction Summary
4
People
8
Organizations
2
Locations
2
Events
6
Relationships
3
Quotes
Document Information
Type:
Document metadata in json format
File Size:
3.32 MB
Summary
The document is JSON code describing an article about the pharmaceutical company Celgene. The article alleges that Celgene used a federal safety program (REMS) to block generic competition for its drugs, Revlimid and Thalomid, leading to lawsuits from companies like Mylan. The text also mentions a patient paying high costs and a professor criticizing Celgene's actions.
People (4)
| Name | Role | Context |
|---|---|---|
| Elaine Kodish | ||
| Emily Berl | ||
| Michael Carrier | ||
| Mr. Menendez |
Organizations (8)
| Name | Type | Context |
|---|---|---|
| Celgene | ||
| The New York Times | ||
| F.D.A. | ||
| Mylan | ||
| Lannett | ||
| Barr Laboratories | ||
| Rutgers Law School | ||
| Quinnipiac |
Timeline (2 events)
Lawsuits filed by generic drug companies against Celgene
New Jersey Senate race
Locations (2)
| Location | Context |
|---|---|
Relationships (6)
→
patient
→
→
litigant
→
→
litigant
→
→
litigant
→
→
critic
→
→
regulated by
→
Key Quotes (3)
"In restricting access to Revlimid and Thalomid, Celgene relied on a federal requirement that the distribution of those drugs be tightly regulated because of their dangerous side effects under a program known as Risk Evaluation and Mitigation System, or REMS."Source
HOUSE_OVERSIGHT_028420.jpg
Quote #1
"Elaine Kodish, who lives in Los Angeles, said she pays $785 a month for Revlimid, a drug produced by Celgene that helps treat her multiple myeloma."Source
HOUSE_OVERSIGHT_028420.jpg
Quote #2
"“This is really concerning conduct and Celgene is by far the worst offender, †Michael Carrier, a professor at Rutgers Law School who studies patent law, said of Celgene’s tactics to delay generic development."Source
HOUSE_OVERSIGHT_028420.jpg
Quote #3
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein document